The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).
Steven Gore
Research Funding - Celgene; GlaxoSmithKline; Novartis
Amy J. Davidoff
Research Funding - Celgene; GlaxoSmithKline; Novartis
Franklin Hendrick
No relevant relationships to disclose
Vu Duong
No relevant relationships to disclose
Bruce C. Stuart
No relevant relationships to disclose
Maria R. Baer
Research Funding - Celgene; GlaxoSmithKline; Novartis
Rahul Shenolikar
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Amer Zeidan
No relevant relationships to disclose